Pharma BD Deal Intelligence
Novo Holdings paid $16.5B for all of Catalent—the world's largest CDMO—to solve Novo Nordisk's GLP-1 supply crisis. With Wegovy and Ozempic demand exceeding manufacturing capacity, this vertical integration play secured dedicated fill-finish capacity that would take years to build organically.
Novo Holdings acquired Catalent for $16.5B for CDMO manufacturing.
Novo Holdings completed its $16.5 billion takeover of Catalent, with the share price representing a premium of approximately 47.5% to the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novo Holdings acquired Catalent for $16.5B for CDMO manufacturing.
Novo Holdings announces $16.5B acquisition of Catalent CDMO to secure manufacturing for Ozempic/Wegovy.
European Commission unconditionally approves; FTC declines to challenge after extended review.
Novo Holdings acquires Catalent at $63.50/share. Largest Danish acquisition ever. Largest healthcare buyout of 2024.
Novo Nordisk acquires Catalent fill-finish sites in Anagni, Bloomington, Brussels for semaglutide production.
Novo Holdings confirms intention to double Catalent size over five years across 40+ CDMO facilities.
Deal secures Novo Nordisk mfg capacity during GLP-1 supply crisis. Catalent retains CDMO independence.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Holdings A/S / Catalent, Inc. (this deal) | 2016 | $16.5B | 68 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |